Pfiz­er picks GLP-1 tablet win­ner: Danuglipron for PhI­II

Pfiz­er chief Mikael Dol­sten told an­a­lysts last month that the Big Phar­ma would “cher­ry-pick the win­ner” be­tween its two mid-stage oral GLP-1s. The drug­mak­er has now done so, say­ing Mon­day that it’s go­ing with danuglipron over lotiglipron.

The choice puts the Big Phar­ma in the multi­bil­lion-dol­lar race to bring the next GLP-1 to mar­ket. Pfiz­er is well be­hind No­vo Nordisk and Eli Lil­ly, both of which start­ed with in­jecta­bles and are near­ing the fin­ish line with oral ver­sions of their drugs as well, which work by curb­ing ap­petite.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER